JQJhonatan Quiñones-Silva

Jhonatan Quiñones-Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jhonatan Quiñones-Silva has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes of patients with low-risk differentiated thyroid cancer with an excellent response to initial therapy

    by Carlos Garcia-Regal, Jhonatan Quiñones-Silva, Noemi Brox-Torrecilla, Alberto Martinez-Lorca, Ignacio Ruz-Caracuel, Héctor Pian Arias, Sonsoles Aso Manso, Ana Maria Garcia Cano, Marta Rosillo, Patricia Luengo, et al.

    Objective: Patients with differentiated thyroid carcinoma (DTC) classified as low risk of recurrence and an excellent response to initial treatment should have a particularly low risk of recurrence. Our objective was to assess the recurrence rate in these patients to support follow-up de-escalation. Methods: A multicenter retrospective study was conducted in six Spanish hospitals, including consecutive patients diagnosed with low-risk DTC between 2015 and 2018 with an excellent response to initial therapy. Results: A total of 379 patients were included, with a median follow-up of 6.7 years. Response to therapy at the last follow-up, according to the 2015 ATA/Momesso criteria, was excellent in 349 patients (92.1%), indeterminate in 29 (7.6%), and biochemical incomplete in 1 (0.3%). The overall incidence of indeterminate response was 11.8 events per 1,000 person-years, peaking at year 3 of follow-up and dropping to nearly zero after year 7. PTC and RAI treatment were associated with a lower probability of developing an indeterminate response (P = 0.02 and P = 0.03, respectively). When applying the 2025 ATA criteria, the excellent response rate increased to 95.8% and neither papillary histology nor RAI treatment was significantly associated (P = 0.07 and P = 0.61, respectively). During follow-up, indeterminate/suspicious findings on ultrasound were observed in 39 patients (10.3%). FNA was performed in 20 of these, none of which found recurrence. Conclusions: Recurrences in patients with low risk of recurrence and an excellent response to initial therapy are extremely infrequent. These data support follow-up de-escalation in this population. Significance statement: In this multicenter retrospective study of low-risk DTC patients with an excellent response to initial treatment, no recurrences were observed among 379 patients after a median follow-up of 6.7 years. The overall incidence rate of indeterminate response was 11.8 events per 1,000 person-years, peaking around year 3 after surgery and progressively declining thereafter, approaching zero after year 7. Using the 2025 ATA response-to-therapy criteria, 95.8% of patients maintained an excellent response at the last follow-up, and no variable was associated with the development of an indeterminate response. These findings support follow-up de-escalation.

  • Determinants of physicians’ risk-benefit perceptions of adjuvant radioactive iodine for differentiated thyroid cancer

    by Carlos Garcia-Regal, Jhonatan Quiñones-Silva, Alberto Martinez-Lorca, Noemi Brox-Torrecilla, Sandra Campos Mena, Teresa Alonso-Gordoa, Joaquín Gómez-Ramírez, Pablo Valderrabano


  • Open Access

    Evaluation of thyroid ultrasound reports’ quality in the Community of Madrid, Spain

    by Pablo Valderrabano, Jhonatan Boris Quiñones Silva, Sandra Campos Mena, Cristina Familiar Casado, María Paz de Miguel Novoa, María Concepción Sanabria Pérez, Elisa Fernández Fernández, Aurelio López Guerra, Marcel Sambo, Patricia Martín Rojas-Marcos, et al.

    Objective To evaluate the current quality of thyroid ultrasound reports in the Community of Madrid. Methods Consecutive thyroid ultrasound reports from patients evaluated in the endocrine outpatient clinics of eight academic hospitals in the Community of Madrid were assessed for quality during 2021 and 2022. Descriptions of eight different features were evaluated: number and axes of dimensions, composition, echogenicity, margins, shape, calcifications and category of suspicion. Features were considered adequately reported if described for all nodules ≥1 cm. The number of correctly reported features was compared by year of data capture (2021 vs 2022), specialty of the informant (radiologist vs endocrinologist), and origin of the report (in-house vs outsourced center). The quality of reports for assessing the need for cytological evaluation and/or growth during follow-up was evaluated. Results A total of 1234 reports were included, 63% from 2021; 82% were issued by radiologists and 89% were issued in-house. Composition and echogenicity were the most frequently reported (79% and 72%, respectively). The rest of the features were appropriately described in less than half of the reports. Forty percent of the reports were good to select nodules for biopsy, 23% had sufficient data to assess growth during follow-up, and only 13% met both quality criteria. The overall quality of reports was worse in outsourced centers (median number of described features 2 vs 4, P < 0.001) and better when issued by endocrinologists (median number of described features 6 vs 3, P < 0.001). Conclusions Most thyroid ultrasound reports issued in the Community of Madrid provide insufficient data to make management decisions regarding thyroid nodules. Abstract Objective To evaluate the current quality of thyroid ultrasound reports in the Community of Madrid. Methods Consecutive thyroid ultrasound reports from patients evaluated in the endocrine outpatient clinics of eight academic hospitals in the Community of Madrid were assessed for quality during 2021 and 2022. Descriptions of eight different features were evaluated: number and axes of dimensions, composition, echogenicity, margins, shape, calcifications and category of suspicion. Features were considered adequately reported if described for all nodules ≥1 cm. The number of correctly reported features was compared by year of data capture (2021 vs 2022), specialty of the informant (radiologist vs endocrinologist), and origin of the report (in-house vs outsourced center). The quality of reports for assessing the need for cytological evaluation and/or growth during follow-up was evaluated. Results A total of 1234 reports were included, 63% from 2021; 82% were issued by radiologists and 89% were issued in-house. Composition and echogenicity were the most frequently reported (79% and 72%, respectively). The rest of the features were appropriately described in less than half of the reports. Forty percent of the reports were good to select nodules for biopsy, 23% had sufficient data to assess growth during follow-up, and only 13% met both quality criteria. The overall quality of reports was worse in outsourced centers (median number of described features 2 vs 4, P < 0.001) and better when issued by endocrinologists (median number of described features 6 vs 3, P < 0.001). Conclusions Most thyroid ultrasound reports issued in the Community of Madrid provide insufficient data to make management decisions regarding thyroid nodules.


  • Open Access

    Unveiling Silent Atherosclerosis in Type 1 Diabetes: The Role of Glycoprotein and Lipoprotein Lipidomics, and Cardiac Autonomic Neuropathy

    by Sara de Lope Quiñones, Manuel Luque-Ramírez, Antonio Carlos Michael Fernández, Alejandra Quintero Tobar, Jhonatan Quiñones-Silva, María Ángeles Martínez García, María Insenser Nieto, Beatriz Dorado Avendaño, Héctor F. Escobar-Morreale, Lía Nattero-Chávez

    Introduction: This study aimed to evaluate whether glycoprotein and lipoprotein lipidomics profiles could enhance a clinical predictive model for carotid subclinical atherosclerosis in patients with type 1 diabetes (T1D). Additionally, we assessed the influence of cardiac autonomic neuropathy (CAN) on these predictive models. Methods: We conducted a cross-sectional study including 256 patients with T1D. Serum glycoprotein and lipoprotein lipidomics profiles were determined using 1H-NMR spectroscopy. Subclinical atherosclerosis was defined as carotid intima-media thickness (cIMT) ≥ 1.5 mm. CAN was identified using the Clarke score. Predictive models were built and their performance evaluated using receiver operating characteristic curves and cross-validation. Results: Subclinical atherosclerosis was detected in 32% of participants. Patients with both CAN and atherosclerosis were older, had a longer duration of diabetes, and were more likely to present with bilateral carotid disease. Clinical predictors such as age, duration of diabetes, and smoking status remained the strongest determinants of subclinical atherosclerosis [AUC = 0.88 (95%CI: 0.84–0.93)]. While glycoprotein and lipoprotein lipidomics profiles were associated with atherosclerosis, their inclusion in the clinical model did not significantly improve its diagnostic performance. Stratification by the presence of CAN revealed no impact on the model’s ability to predict subclinical atherosclerosis, underscoring its robustness across different risk subgroups. Conclusions: In a cohort of patients with T1D, subclinical atherosclerosis was strongly associated with traditional clinical risk factors. Advanced glycoprotein and lipoprotein lipidomics profiling, although associated with atherosclerosis, did not enhance the diagnostic accuracy of predictive models beyond clinical variables. The predictive model remained effective even in the presence of CAN, highlighting its reliability as a screening tool for identifying patients at risk of subclinical atherosclerosis.